Iprixon

Ipratropium bromide / Salbutamol, the active ingredient in Iprixon, is a bronchodilator (Anticholinergic / Short‑acting β2‑agonist) presented as a combination inhalation solution for inhalation use. It provides rapid airway relaxation and is indicated for reversible bronchospasm in asthma and chronic obstructive pulmonary disease. The product is delivered via a metered‑dose inhaler designed for precise dosing.

GNH USA supplies Iprixon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality assurance and regulatory standards.

Iprixon, a bronchodilator combination, is indicated for conditions involving reversible airway obstruction.

- Asthma: provides rapid relief of bronchospasm and improves airflow during acute episodes. - Chronic obstructive pulmonary disease (COPD): reduces bronchoconstriction and eases breathing in acute exacerbations. - Exercise‑induced bronchospasm: delivers quick bronchodilation to prevent symptoms triggered by physical activity.

Iprixon may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Cough or throat irritation: mild irritation of the upper airway after inhalation. - Dry mouth: reduced salivary secretion leading to a dry sensation. - Tremor: fine shaking of the hands, especially at higher doses. - Headache: mild to moderate headache episodes. - Palpitations: sensation of rapid or irregular heartbeat. - Nausea: occasional feeling of stomach upset.

Serious or Rare Side Effects: - Paradoxical bronchospasm: worsening of breathing difficulty after use. - Tachyarrhythmia: rapid heart rhythm that may require medical attention. - Angina pectoris: chest pain due to reduced cardiac blood flow. - Severe hypotension: marked drop in blood pressure. - Anaphylactic reaction: life‑threatening allergic response with rash, swelling, and airway compromise. - Hyperglycaemia: elevated blood glucose levels, particularly in diabetic patients.

Before prescribing Iprixon, clinicians should consider several precautionary measures to ensure safe use.

- Cardiac history: evaluate patients with arrhythmias or ischemic heart disease for possible tachycardia or angina. - Thyroid disease: monitor hyperthyroid patients as β2‑agonists may exacerbate symptoms. - Diabetes: observe blood glucose as salbutamol can raise glucose levels. - Elderly patients: start with the lowest effective dose and watch for increased sensitivity to anticholinergic effects. - Concomitant β‑blockers: avoid use with non‑selective β‑blockers as they may diminish bronchodilator response. - Store at room temperature: keep the inhaler below 25 °C, protect from moisture and direct sunlight, and retain in the original packaging.

Iprixon can interact with other medicines; awareness of major and moderate interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Non‑selective β‑blockers: may antagonize salbutamol’s bronchodilatory effect and precipitate bronchospasm. - MAO inhibitors or tricyclic antidepressants: can potentiate salbutamol‑induced cardiovascular effects. - Anticholinergic drugs: combined use may increase anticholinergic burden leading to dry mouth, urinary retention, or glaucoma.

Moderate Interactions (Monitor Closely): - Diuretics (e.g., thiazides): may enhance hypokalemia risk when combined with salbutamol. - Theophylline: concurrent use may increase the likelihood of tachyarrhythmias. - Monoamine oxidase inhibitors: may require dose adjustment of salbutamol. - Other inhaled bronchodilators: overlapping therapy can increase side‑effect risk; monitor patient response.